Mini-Oral Session

[MO37] Mini-Oral Session 37　Cross-sectional Program 3（Clinical practice of immuno-check point inhibitor）
【E】

Sat. Feb 19, 2022 8:20 AM - 9:10 AM Room 7 (Room E, 1F, Kyoto International Conference Center)

Chair：Yasumasa Nishimura（Department of Radiation Oncology, Kindai University），Masato Masuda（Cancer Centre, University of the Ryukyus Hospital）

+Add all to schedule

[MO37-1] Treatment outcome and relapse of serious immune-related adverse events in patients with solid malignancies

^○Seira Owaki¹, Kazuhiro Shiraishi¹, Mariko Sato¹, Riko Nishibori¹, Kyoko Kato¹, Keiji Sugiyama¹, Yoriko Funahashi¹, Miki Yoshida³, Hirotaka Inoue⁴, Yoshihito Kogure¹, Nobuyoshi Minemura², Chiyoe Kitagawa¹ (1.Department of Medical Oncology, Nagoya Medical Center, 2.Division of General Internal Medicine, Mitsui Memorial Hospital, 3.Department of Nursing, Nagoya Medical Center, 4.Division of Administration, Clinical Research Center, Nagoya Medical Center)

[MO37-2] Retrospective study of the efficacy and safety of Pembrolizumab for solid tumors with MSI-High

^○Takako Ikegami¹, Fukutaro Shimamoto¹, Masahiro Goto¹, Tetusuji Terazawa¹, Eiki Yamasaki¹, Kazuhide Higuchi² (1.Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, 2.Osaka Medical and Pharmaceutical University, 2nd Department of Internal Medicine)

[MO37-3] Clinical characteristics of 145 patients with adrenal insufficiency related to immune checkpoint inhibitor

^○Miyuki Uoi¹, Junko Tauchi², Kaoru Koshiba⁴, Daisuke Hisamatsu¹, Atsushi Miyada⁵, Haruna Kameoka⁵, Shinya Takada⁶, Takuya Hiromasa⁶, Reiko Matsui², Ken Ohashi³, Toshikatsu Kawasaki² (1.Department of Pharmacy, National Hospital Organization Kyushu Cancer Center, 2.Department of Pharmacy, National Cancer Center Hospital East, 3.Department of General Internal Medicine, National Cancer Center Hospital, 4.Department of Pharmacy, National Cancer Center Hospital, 5.Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, 6.Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center)

[MO37-4] Safety of immune checkpoint inhibitor rechallenge after grade≥2 immune-related adverse events in the real world

^○Machiko Kawahira¹, Shiho Arima², Shuji Kanmura², Shinsuke Suzuki³, Shinichi Ueno³, Akio Ido² (1.Department of Gastroenterology, Kagoshima Kouseiren Hospital, 2.Department of digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 3.Department Of Clinical Oncology, Kagoshima University Graduate School of Medical and Dental Sciences)

[MO37-5] Hematologic toxicities induced by Immune checkpoint inhibitors: a single-center, retrospective study

^○Sayako Yuda, Tada Yuma, Shingai Yasuhiro, Fuji Shigeo, Masaie Hiroaki, Ishikawa Jun (Department of Hematology, Osaka International Cancer Institute)

[MO37-6] Clinical safety of nivolumab 480 mg once every 4 weeks

^○Taisuke Hosokai, Motoo Nomura, Masashi Tamaoki, Yosuke Mitani, Kenshiro Hirohashi, Masahiro Yoshioka, Taro Funakoshi, Akira Yokoyama, Junichi Matsubara, Yukiko Mori, Atsushi Yamada, Masashi Kanai, Reiko Kimura, Shigemi Matsumoto, Manabu Muto (Department of Medical Oncology, Hospital Kyoto University)